RESTORE study highlights persistent vision recovery in patients with LHON with MT-ND4 mutation
January 4th 2025The multinational, multicenter, prospective RESTORE Study is the 5-year follow-up study of the phase 3 clinical RESCUE and REVERSE Studies of lenadogene nolparvovec to treat vision loss from LHON due to the MT-ND4 mutation.
Read More
Microdrops show promise for safer retinopathy of prematurity screening in preterm infants
January 3rd 2025The rationale was that commercial mydriatics administered during retinopathy of prematurity (ROP) screening have been associated with cardiorespiratory and gastrointestinal adverse events.
Read More
Relapse in ocular tuberculosis: Study reveals one-third of cases resurface after treatment
November 29th 2024About 33% of ocular tuberculosis patients may relapse within 2 years of achieving clinical inactivity, with a poor initial treatment response serving as a strong predictor of recurrence.
Read More